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Background: The objective of this study is to perform an independent evaluation of the feasibility and
effectiveness of an educational programme for the primary prevention of type 2 diabetes (DM2) in high risk
populations in primary care settings, implanted within the Basque Health Service - Osakidetza.
Methods/design: This is a prospective phase IV cluster clinical trial conducted under routine conditions in 14
primary health care centres of Osakidetza, randomly assigned to an intervention or control group. We will recruit a
total sample of 1089 individuals, aged between 45 and 70 years old, without diabetes but at high risk of
developing the condition (Finnish Diabetes Risk Score, FINDRISC ≥ 14) and follow them up for 2 years. Primary
health care nursing teams of the intervention centres will implement DE-PLAN, a structured educational
intervention program focused on changing healthy lifestyles (diet and physical activity); while the patients in the
control centres will receive the usual care for the prevention and treatment of DM2 currently provided in
Osakidetza. The effectiveness attributable to the programme will be assessed by comparing the changes observed
in patients exposed to the intervention and those in the control group, with respect to the risk of developing DM2
and lifestyle habits. In terms of feasibility, we will assess indicators of population coverage and programme
implementation.
Discussion: The aim of this study is to provide the scientific basis for disseminate the programme to the remaining
primary health centres in Osakidetza, as a novel way of addressing prevention of DM2. The study design will enable
us to gather information on the effectiveness of the intervention as well as the feasibility of implementing it in
routine practice.
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Type-2 diabetes (DM2) has become one of the main
causes of morbidity and early mortality in most coun-
tries, associated especially with a higher risk of cardio-
vascular diseases. Further, it is expected that the
prevalence of DM2 will double by 2030 and that this
condition will become the seventh cause of death world-
wide [1]. Cardiovascular morbidity and mortality in indi-
viduals with DM2 is much higher than in the general
population. The mortality rate associated with diabetes
ranges between 13 and 30 deaths per 100,000 people per
year, the main cause of death being coronary disease [2].
It has also been estimated that half of the population of
Europe will have hyperglycaemia or diabetes during their
lives [3], these conditions becoming more prevalent
among both elderly and young people, with a sudden in-
crease in those below 30 years of age [4]. This dramatic
increase in the recently diagnosed cases of DM2 and its
complications have become an important public health
problem and affect almost all populations in both devel-
oped and developing countries [1,5].
In recent years, several clinical trials have demon-
strated that is possible to prevent DM2 through educa-
tional interventions to change lifestyles. Specifically, in
high risk subjects, the risk of developing DM2 can be
reduced by around 60% after 3 years of these types of
intervention [6-8]. Additionally, the effects of interven-
tions focused on changing lifestyles seem to last in the
long-term [9,10]. The findings of these studies are re-
vealing. However, the evidence has been obtained from
large controlled clinical trials, with well-developed infra-
structure and considerable resources. It is not clear
whether more realistic interventions, feasible under nor-
mal working conditions in health systems, would lead to
results similar to those in the aforementioned large trials
[11,12]. Therefore, the key question is: can the efficacy
demonstrated in clinical trials be replicated in normal
clinical working conditions, with much lower resources
for the implementation of these types of programmes
and interventions?
The step after testing the efficacy of a new experimen-
tal intervention, with phase III clinical trials, is the as-
sessment of its effectiveness, efficiency and long-term
sustainability under real conditions, with phase IV trials
[13]. Unfortunately this step is not at all easy. The wide-
spread adoption of this type of health intervention does
not automatically follow from research proving its effi-
cacy, let alone in the specific context of primary health
care, characterised by work overload, with shortages of
time and training. In recent years, there have been sev-
eral initiatives assessing the transfer of interventions
related to the promotion of healthy lifestyles for the pre-
vention of DM2 to the real context of primary health-
care [14-20]. Some of these have indicated that it isfeasible to reduce the risk of developing DM2 in several
routine clinical settings. In most cases, however, the
studies were not based on group comparisons, were not
set up and implemented under real-world conditions in
primary care settings or relied in additional resources,
and/or did not include the reduction in the incidence of
DM2 among the outcome variables. Despite evidence
from experimental trials, the translation of lifestyle inter-
ventions into routine practice appears to have no effect
on diabetes risk reduction [21].
Recently, The Diabetes in Europe-Prevention using
Lifestyle, Physical Activity and Nutritional Intervention
project (DE-PLAN), has been launched within the
Spanish National Health Service [22]. This is a public
health study focused on evaluating the implementation of
a programme developed and implemented in the primary
care setting involving: 1) a screening programme for iden-
tifying individuals at high risk of developing DM2; 2) an
integrated programme with various different intensive
interventions for changing lifestyles among high risk
individuals; 3) an ongoing intervention programme for
maintaining the motivation of participants; and 4) a
programme for assessing the feasibility and cost-
effectiveness of the aforementioned screening and inter-
vention programmes, in different European primary care
systems. The only results published so far concerning the
DE-PLAN study conducted in Madrid are exclusively
related to the participants in the intervention group, with
no comparison group, so that the results obtained cannot
be attributed to the programme [23]. One year after the
intervention, about 7% of patients in the intervention
group developed clinical features of DM2, similar to the
figures reported for the control groups in two large DM2
prevention trials [6,7]. More recently, the researchers of
the DE-PLAN project in Catalonia [24] have demon-
strated that an intensive intervention for the promotion of
healthy lifestyles is feasible in the context of primary care
and does significantly reduce the prevalence of DM2
among high risk individuals. After a mean follow-up of
4.2 years, the incidence of DM2 was 7.2 and 4.6 cases per
100 people per year, for usual care and intensive interven-
tion groups, respectively (equivalent to a 36.5% reduction
in relative risk). In this study, patients were randomly
selected previously to inclusion and centres were asked to
assign subjects who agreed to take part in the programme
consecutively to comparison groups if feasible. The fact
that it is an observational study limits its ability to confirm
the effectiveness of the programme in real-world primary
care settings.
In short, the methodological limitations and mixed
results of studies evaluating the effects of primary DM2
prevention programmes in primary care raise doubts as
to whether the implementation of these programmes in
normal working conditions in health centres would
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cordingly, prior to widespread implementation, the
transfer to real-word settings should be evaluated with a
scientifically valid design. The transfer of effective and
sustainable interventions to routine clinical practice
remains one of the greatest challenges in scientific re-
search in the field of DM2 prevention [12].
The “Prevention of Diabetes in Euskadi” project
(PreDE) aims to perform an experimental evaluation of
the implementation of a programme for the primary pre-
vention of DM2, through the promotion of healthy life-
styles in patients at high risk of developing the disease,
under normal working conditions in primary care. The
project is based on the DE-PLAN programme and its
methodology, though it has been adapted to the
OSAKIDETZA centres. The primary objective is to as-
sess the effectiveness and feasibility of the programme in
the routine clinical practice of the centres and health





The general objective of the study is to perform an inde-
pendent scientific evaluation of the impact of the imple-
mentation of an educational programme for the primary
prevention of DM2 in high-risk populations seen in
OSAKIDETZA primary care centres. This general ob-
jective can be broken down into several specific
objectives:
i) to evaluate the results of the intervention
programme in terms of reduction in the incidence
of DM2, change in dietary habits, and increase in
physical activity, among high-risk individuals
attending OSAKIDETZA primary care centres in
which the programme has been implemented.
ii) to estimate the effectiveness attributable to the
intervention, comparing its results with those of
patients seen in control centres where patients will
receive the current usual care.
iii) to assess the feasibility of the intervention (in terms
of coverage, adoption and implementation) in the
OSAKIDETZA primary care centres.
Hypotheses
i) The implementation of a DM2 prevention
programme based on an intervention to promote
healthy lifestyles, physical activity and diet, carried
out under normal working conditions in the primary
care setting over a period of 12 months, will reduce
the incidence of DM2 in high risk individuals by50%, compared to that in a control group of high
risk individuals who receive standardised usual care
for the prevention of DM2. The expected reduction
in the incidence, 50%, a clinically significant
difference, is based on previous studies on DM2
prevention in other countries [6,7,24].
ii) In line with the DE-PLAN data from Spain [23], we
expect that 50% of the patients exposed to the
intervention programme will meet the recommended
levels of physical activity (30 minutes of physical
activity at least 5 times a week) and consumption of
fruit and vegetables (at least 5 portions a day). In the
control group, we expect that 25% of patients will
meet the minimum recommendations.
Study design
This is a phase IV randomized cluster clinical trial con-
ducted in 14 Osakidetza primary care centres, randomly
assigned to the intervention or control groups. The same
system for identifying high-risk patients will be set up in
all the centres, based on the administration of the 8-
item Spanish version of the validated European Finnish
Diabetes Risk Score (FINDRISC) [25]. Non-diabetic
patients aged between 45 and 70 years old who are iden-
tified as at high-risk of developing DM2 (FINDRISC
score ≥14) will be invited to participate in a follow-up
programme lasting 24 months with annual medical
check-ups. Additionally, a sub-sample of included
patients will complete an independent, telephone inter-
view carried out by blind external interviewers on diet-
ary habits and level of physical activity at baseline and
again after 12 months.
Primary care nursing professionals from the seven
intervention centres have set up the DE-PLAN
programme (for the intervention groups, IGs), adapted
to the setting and normal working conditions in the
health centres in OSAKIDETZA. Patients found to be at
high risk of developing DM2 (FINDRISC score ≥ 14)
who then complete the baseline assessments at these
intervention centres will be invited to participate in the
DE-PLAN programme; while those in the control health
centres, will receive usual care for the prevention and
treatment of DM2 (Figure 1).
Setting
The PreDE initiative is one of the strategic projects of
the “Strategy for Tackling the Challenge of Chronicity in
the Basque Country” of the Department of Health of the
Government of the Basque Country [26]. This Depart-
ment decided to commission a pilot study of the imple-
mentation of the DE-PLAN programme in 14 primary
care centres of OSAKIDETZA and fund an independent
assessment of the results, to provide a basis for its future
dissemination to the remaining primary care health
Figure 1 Flow of the study.
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the Basque Country. This protocol concerns to the de-
sign of the independent scientific assessment of the im-
plementation of this prevention programme for diabetes
under normal clinical conditions in the OSAKIDETZA
primary care centres. The research protocol has been
approved by the Basque Country Clinical Research
Ethics Committee (Ref. no.: 10/2010). The Basque
Healthcare Service (Osakidetza) provides universal freecoverage, aside from co-payment for drugs, funded
through regional general taxation. In Spain healthcare is
a constitutionally-guaranteed right, the public system
dominates the healthcare market and primary care ser-
vices are almost exclusively supplied in public facilities.
Each citizen is included in the list of one family phys-
ician or pediatrician who offers comprehensive primary
care and constitutes the access gate by referral to hos-
pital services. Primary care professionals work in full-
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cians, pediatricians, nurses, and administrative staff
hosted in centers and serving with extensive accessibility
to a defined geographical area. Healthcare professionals
have a civil-servant type labor status and they are paid a
fixed salary with a small capitation supplement for
physicians.
Participants
Primary care centres In each of the seven health
regions in which the Basque Health Service is organized,
we selected a convenience sample of two centres, similar
in terms of structure and population covered. After
explaining the objectives of the project and working plan
in a presentation session in each of the candidate cen-
ters, those professionals who wanted to collaborate
signed a written commitment form individually. The 14
centres have been randomly assigned to the intervention
and control groups, stratified on a 1:1 basis for each
health region, using computer-generated random num-
bers provided by the Primary Care Research Unit of
Bizkaia, such that in each health region there is one
intervention and one control group.
Primary healthcare users All users aged between 45
and 70 years old, without diabetes, who attend one of
the participating health centres for any reason case dur-
ing the period of implementation of the programme are
eligible to participate. Exclusion criteria are: Previous
diagnosis of diabetes mellitus other than gestational; To
participate regularly in vigorous exercise programs; Hav-
ing a chronic disease that makes survival at 6 years un-
likely; Patients with diseases that could interfere with
the metabolism of glucose.
Recruitment process
The 14 centres will implement a system for identification
and screening of all eligible patients based on the
FINDRISC scale. Eligible individuals with no exclusion
criteria who have a score ≥ 14 on the FINDRISC scale, in-
dicating that they are at high risk of developing DM2, will
be invited to participate in the study and given the patient
information sheet. This explains that they will be
followed-up for a period of 24 months with annual med-
ical check-ups consisting of blood lipid profile and glu-
cose tolerance tests. In addition, to those belonging to
intervention centres it provides information on the inter-
vention protocol. Patients who agree to participate and
sign an informed consent form, will be invited to perform
an oral glucose tolerance test (OGTT) with 75 g of glu-
cose in accordance with the WHO guidelines and a deter-
mination of lipid profile and HbA1C. Centre’s nurses will
measure body weight, height, and waist circumference.Patients who after the test are diagnosed with DM2 will
be seen by their family physician and excluded from the
study. High-risk patients with glucose levels below
200 mg/ml in the OGTT will be included in the study.
A sub-sample of consecutive included patients once a
full implementation of the program in centres is guaran-
teed (e.g., three months after study initiation), will
undergo an independent baseline assessment by blind
certified interviewers of their dietary habits and level of
physical activity. In order to minimise selection bias,
interviewers will make up to six telephone calls at differ-
ent times of day and on different days in the week in an
attempt to contact these individuals, until they are inter-
viewed or are classified as “not contactable”. Non-
contactable patients will not be substituted.
Intervention standardisation
Common treatment for both groups in the study Both
comparison groups will implement the same procedures
for screening and initial assessment (clinical examin-
ation, blood lipid analysis, and an OGTT with 75 g of
glucose, following the WHO guidelines) as well as an-
nual check-ups at the health centres.
DE-PLAN educational intervention group The
DE-PLAN educational intervention programme for pro-
moting healthy lifestyles (mainly diet and physical exer-
cise) is carried out by nurses. The intervention is designed
to achieve at least three out of the five following objec-
tives: 1) maintenance of ideal body weight in people with
normal weight and loss of >5% of body weight in those
who are overweight or obese; 2) fat intake <30% of the
daily energy intake, 3) intake of saturated fats <10% of the
daily energy intake, 4) intake of fibre >15 g/1000 kcal/day,
and 5) physical activity >4 hours per week. The interven-
tion is performed in two phases:
a) Intensive intervention through educational sessions in
small groups on the modification of unhealthy and
adoption of healthy habits. This phase comprises four
group sessions of 1.5 hours each. Its objective is to
motivate participants to adopt healthy lifestyle habits
and provide information concerning the most suitable
diet and exercise, as well as agreeing on specific
objectives for eating habits and physical activity.
b) Continuous reinforcement for maintaining
motivation through regular contact with
participants. Once the intensive education
intervention programme has been completed, the
participants will regularly (at least once every
6 weeks) receive reinforcing educational information
via telephone calls, e-mails, etc. from nurses through
a health communication platform.
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received a 14-hour training course focused on the content
and procedures for the educational intervention. Add-
itionally, they have received a five-hour training course on
the procedures for screening and identifying patients.
Control group The nurses in charge of the control
group will continue the current practice and provide the
usual care with advice on healthy habits as part of the
prevention and treatment of DM2, based on the current
clinical practice guidelines of Osakidetza. Given that the
system for screening and identifying patients is the same
in both groups, the healthcare professionals of the con-
trol groups also received the five-hour training course.
Evaluation of results
Effectiveness of the intervention among patients The
primary outcome variable will be the relative risk of
developing DM2, comparing the accumulated incidence
(assessed by the OGTT) in the intervention and control
groups after 24 months. The secondary outcome vari-
ables will be observed changes at 12 months in a sub-
sample of intervention and control patients in: the pro-
portion of patients who meet the recommended aerobic
physical activity levels (moderate-intensity physical ac-
tivity for ≥ 30 minutes 5 days/week or vigorous intensity
activity for ≥ 20 minutes 3 days/week), derived from the
7-day Physical Activity Recall questionnaire [27]; and the
proportion of patients who consume ≥ 5 servings of
fruits and vegetables, assessed by the Mediterranean Diet
Adherence Screener (MEDAS) used in the ‘Prevención
con Dieta Mediterránea (PREDIMED)’ study [28]. Lastly,
potential effect-modifying variables will be also mea-
sured: age, sex, and level of education, among others.
Feasibility of the implementation of the programme
and its components The following indicators will be
assessed: a) adoption of the programme, in terms of per-
centage of health professionals that carry out various dif-
ferent components of the intervention; representativeness,
dropout rate, causes and degree of influence of the drop-
out rate on outcomes; b) reach of the programme, in term
of percentage of patients exposed to the programme,
dropout rate, causes and degree of influence of the drop-
out rate on the outcomes; and c) implementation of the
components of the programme, in terms of degree to
which participating patients had received the various dif-
ferent components of the programme as planned.
Data quality and management
The coordination, control of quality of processes related
to the study, data management and quality assurance
will be the responsibility of the Primary Care ResearchUnit of Bizkaia. The OGTT will be performed in the
corresponding health centres or reference laboratory,
and results recorded in patient medical records. Changes
in lifestyle habits of participants will be assessed by
trained professional interviewers, blind to the assign-
ment of patients to the comparison groups, under the
supervision of the research team. Data will remain an-
onymous and only be used for the purpose of this re-
search. Confidentiality of the subjects participating in
the study will be maintained in compliance with the
Spanish Organic Law 15/1999 on Personal Data Protec-
tion (of the 13th December).
Sample size
Considering the most conservative results found among
high-risk patients in DM2 prevention projects in other
countries [6,7] and the most recent data reported from
the DE-PLAN project in Catalonia [24], the expected
two-year incidence is 15% in the control group. Assuming
that the percentage of people diagnosed with DM2 at
24 months will be 15% and 7.5% in the control and ex-
perimental groups respectively, and assuming a propor-
tion of 60% recruited patients in the control group with
respect to the total sample, to achieve a power of 80% to
detect a 50% reduction in the incidence of DM2 as sig-
nificant, by a Chi square test for independent samples
with a two-sided p < 0.05, we need a recruitment under
routine conditions of 355 and 237 patients in the control
and intervention centres, respectively. However, if we as-
sume that 15% of participants were to be lost to follow-
up and an intra-class correlation of 0.01, given that this is
a cluster-randomised clinical trial, the number of patients
required would be 653 in the control group and 436 in
the intervention group, that is, 1089 in total. A sample of
360 patients, 180 in each comparison group, will provide
a statistical power of at least 90% to detect, as significant
with p <0.05, differences of 50% in the percentage of
patients who follow the minimum recommendations of
physical activity and servings of fruit and vegetables.
Analysis
Statistical analysis will be carried out using the SAS
package (version 9.2; SAS Institute, Cary, NC; 2008).
The percentages of diagnosed diabetes at 12 and
24 months after the inclusion in the study will be calcu-
lated and the level of association with exposure to the
educational intervention, considering the potential con-
founders, will be assessed. Multiple logistic regression
analyses will be performed on the percentage of patients
diagnosed of diabetes at 24 months, adjusting for inter-
vention group, socio-demographics (age, sex, etc.), and
baseline clinical variables (BMI, BP, lipid profile values,
etc.). Odds ratios (ORs) and the corresponding 95% con-
fidence intervals (CIs) will be calculated.
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until diagnosis of diabetes in the different groups. To as-
sess the univariate association of the time until diagnosis
of diabetes with the comparison groups and with other
possible predictors, cumulative survival probabilities in
the 24 months will be estimated and compared using
Kaplan-Meier curves along with the log-rank and Wil-
coxon tests (SAS PROC LIFETEST, version 9.2, SAS In-
stitute; 2008). Person-years will be the sum of time
under follow-up for all participants before diabetes diag-
nosis or end of follow-up if free of developing diabetes.
Subjects who withdrew from the study will be consid-
ered to be at risk for diabetes until their last oral glucose
tolerance. However, an effort will be made in order to
ascertain a diabetes diagnosis at the end of the study
period reviewing patients’ charts. Adjusted hazard ratios
(AdHRs) and 95% CIs will be estimated to compare
diagnosis of diabetes risks between patients in different
groups using Cox proportional hazards models introdu-
cing all the variables studied in the bivariate analysis as
potential confounders. The proportional hazard assump-
tion will be assessed using graphical techniques and a
statistical test based on Schoenfeld partial residuals of
the model. In the case of covariates for which the pro-
portional hazard assumption is not satisfied, the Cox
model will be extended with time-dependent variables
allowing hazard ratios to change over time. Finally, to
model the clustered structure of data, a common ran-
dom effect will be introduced into the Cox’s propor-
tional hazards model. This estimation will be carried out
by adaptive Gaussian quadrature method implemented
in SAS PROC NLMIXED.
As for the secondary outcome variables, the differ-
ences between the groups will be estimated and 95%
confidence intervals calculated. The mean changes of
the continuous variables will be compared by Student’s
t-tests, while differences in proportions will be com-
pared by chi Square tests. In the case of non-normal
distribution of data non-parametric tests will be used.
Generalized mixed-effects models will be used to esti-
mate baseline and multivariate adjusted between-group
differences, adjusted odds ratios (AORs), and 95%
confidence intervals (CIs) at the patient level, taking
into account the hierarchical and multi-center structure
of data.
Discussion
This study is to be an independent assessment of the
results of the implementation of a prevention programme
for DM2 in high-risk populations seen in 14 primary care
centres in the Basque Health Service, Osakidetza, com-
missioned by the Department of Health of the Govern-
ment of the Basque Country. The scientific evidence
provided by this study may be unique internationally as ithas not, so far, been demonstrated that a programme for
preventing DM2, implemented under real conditions in
primary health care centres, is able to prevent the devel-
opment of DM2 in high-risk patients.
Despite the promising results of the studies of DM2
prevention in routine clinical setting available to date
[14-18,21], transferring effective, sustainable and accept-
able interventions to routine clinical practice in primary
care remains a challenge. The transfer and application of
research to clinical practice is a complex process [29]
that requires planning at individual and organisational
levels [30]. On the other hand, health professionals work
in specific organisational and structural contexts within
a system and there are a wide range of factors that may
facilitate or impede change [31-33].
Despite the Basque Health System having already
entered into a period of change due to new health policies
focused on addressing the issues associated with chron-
icity [26], the implementation of any new programme in
routine clinical conditions is an extra challenge that
requires those involved to adapt and barriers to change to
be overcome [32,33]. The strategy for the implementation
of the present programme for preventing diabetes in rou-
tine practice has mainly involved the training of nurses.
Additionally, materials and resources for data manage-
ment have been provided and health professionals have
been encouraged to optimise the way they work together.
It remains to be seen whether these passive strategies are
enough to enable the successful implementation of the
programme, and ensure that it is sustainable over time by
the health centres, has sufficient reach in the target popu-
lation, and is effective in terms of patient health. Specific-
ally, in the light of results of other studies, various
difficulties can be envisaged that would influence the im-
plementation of the programme and potentially its
results: these relate to the degree of adoption among pri-
mary care health professionals, patient recruitment during
routine clinical practice in the intervention centres, in-
cluding a lack of willness of patients to participate, pro-
blems in the organisation of educational groups, and
losses to follow-up, as well as the many external barriers
to change with regards to lifestyle habits [12,21].
The present study is intended to generate valid scien-
tific data concerning the effectiveness of a programme
promoting healthy lifestyles for the prevention of type 2
diabetes in the real world of primary care. It also sets
out to assess the feasibility of the programme in terms
of reach, adoption and implementation in the routine
clinical context and provide data on the many strategies
used in the course of its implementation. The results
obtained, if positive, will be used to facilitate the process
of rolling out the programme to all the primary care
centres of the Osakidetza as a new approach to prevent-
ing DM2.
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